MetaCap

Acumen Pharmaceuticals Inc. (ABOS)

NASDAQ: ABOSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.1865-0.0068 (-3.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABOS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$13.49M
EPS (TTM)
-$1.55
52-week range
0.16 – 3.60
Day range
0.1601 – 0.1927
Volume / Avg
2.71M / 2.73M
Beta
—

52-week range

$0.16$3.60

ABOS stock today

On Nov 20, ABOS ended the session at $0.1865, shedding $0.0068 (3.52%), versus the S&P 500's 3.70% decline. Shares are 94.8% below their 52-week high of $3.60, set on Mar 16, 2026 and 16.6% above the 52-week low of $0.16, near the bottom of the past year's range. ABOS is down 91.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 88.1%.

Acumen Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Acumen Pharmaceuticals

Company profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Daniel J. O'Connell M.B.A.
Headquarters
Newton, MA
Employees
60
IPO year
2021

Financial highlights

Full financials

Acumen Pharmaceuticals reported a net loss of $121.3 million, compared with a loss of $102.3 million a year earlier. Diluted earnings per share came in at -$2.00.

Acumen Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-121.33M$-102.33M$-52.37M$-42.86M$-100.61M
EPS (diluted)$-2.00$-1.71$-1.08$-1.06$-5.02

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$7.60+3975.07%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 26, 2026
EPS actual vs est.
$-0.35 vs $-0.43
Surprise
+18.60%

ABOS news

All ABOS news

Acumen Pharmaceuticals peers

Health Care sector
ABOS peer companies
CompanyPrice% ChgMarket capCompare
PLURPluri Inc.0.94-3.07%$13.51Mvs ABOS
ESLAEstrella Immunopharma Inc.0.321-5.70%$14.11Mvs ABOS
PASGPassage Bio Inc.3.92+11.68%$12.61Mvs ABOS
BSEMBioStem Technologies Inc.0.6351-10.23%$12.18Mvs ABOS
BCDABioCardia Inc.0.785+1.60%$11.88Mvs ABOS
DYAIDyadic International Inc.0.287-7.66%$11.51Mvs ABOS
TCRXTScan Therapeutics Inc.0.1459+2.24%$9.89Mvs ABOS
ATYRaTyr Pharma Inc.3.82+3.52%$9.74Mvs ABOS

Indexes, lists and sector

Acumen Pharmaceuticals stock FAQ

What is Acumen Pharmaceuticals's stock price today?

ABOS last traded at $0.1865 as of Nov 20, 4:00 PM EST, down 3.52% on the day. Prices are delayed at least 15 minutes.

Who is Acumen Pharmaceuticals's CEO?

Mr. Daniel J. O'Connell M.B.A. is the chief executive officer of Acumen Pharmaceuticals Inc., which has about 60 employees.

What is the ABOS 52-week high?

The 52-week high for ABOS is $3.60 and the 52-week low is $0.16. The stock is currently 94.8% below its high.

Compare ABOS